Literature DB >> 22414082

Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application.

F Rödel1, B Frey, U Gaipl, L Keilholz, C Fournier, K Manda, H Schöllnberger, G Hildebrandt, C Rödel.   

Abstract

During the last decade, a multitude of experimental evidence has accumulated showing that low-dose radiation therapy (single dose 0.5-1 Gy) functionally modulates a variety of inflammatory processes and cellular compounds including endothelial (EC), mononuclear (PBMC) and polymorphonuclear (PMN) cells, respectively. These modulations comprise a hampered leukocyte adhesion to EC, induction of apoptosis, a reduced activity of the inducible nitric oxide synthase, and a lowered oxidative burst in macrophages. Moreover, irradiation with a single dose between 0.5-0.7 Gy has been shown to induce the expression of X-chromosome linked inhibitor of apoptosis and transforming growth factor beta 1, to reduce the expression of E-selectin and L-selectin from EC and PBMC, and to hamper secretion of Interleukin-1, or chemokine CCL20 from macrophages and PMN. Notably, a common feature of most of these responses is that they display discontinuous or biphasic dose dependencies, shared with "non-targeted" effects of low-dose irradiation exposure like the bystander response and hyper-radiosensitivity. Thus, the purpose of the present review is to discuss recent developments in the understanding of low-dose irradiation immune modulating properties with special emphasis on discontinuous dose response relationships.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414082     DOI: 10.2174/092986712800099866

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  69 in total

Review 1.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Radiation takes its Toll.

Authors:  Josephine A Ratikan; Ewa D Micewicz; Michael W Xie; Dörthe Schaue
Journal:  Cancer Lett       Date:  2015-03-25       Impact factor: 8.679

3.  Reply to Little et al.: dose-responses from multi-model inference for the non-cancer disease mortality of atomic bomb survivors.

Authors:  H Schöllnberger; J C Kaiser; L Walsh; P Jacob
Journal:  Radiat Environ Biophys       Date:  2013-01-12       Impact factor: 1.925

4.  The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome. Long-term results.

Authors:  O J Ott; S Hertel; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

5.  Effects of low-dose-gamma rays on the immune system of different animal models of disease.

Authors:  Noriko Shimura; Shuji Kojima
Journal:  Dose Response       Date:  2014-04-23       Impact factor: 2.658

Review 6.  The melatonin immunomodulatory actions in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; Gh Geraily; F Norouzi; M Heidari; S Rezapoor
Journal:  Biophys Rev       Date:  2017-03-27

7.  ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.

Authors:  Amanda C Freise; Kirstin A Zettlitz; Felix B Salazar; Xiang Lu; Richard Tavaré; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

8.  Radiotherapy for calcaneodynia. Results of a single center prospective randomized dose optimization trial.

Authors:  O J Ott; C Jeremias; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

9.  Commentary on fukushima and beneficial effects of low radiation.

Authors:  Jerry M Cuttler
Journal:  Dose Response       Date:  2013-05-24       Impact factor: 2.658

10.  Uncomfortable issues in radiation protection posed by low-dose radiobiology.

Authors:  Carmel Mothersill; Colin Seymour
Journal:  Radiat Environ Biophys       Date:  2013-05-15       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.